Skip to main content

Month: September 2022

Smart Building Market Trends, Size [2022-2029] Worth USD 328.62 Billion | Exhibiting a CAGR of 22.2%

According to Fortune Business Insights, the global Smart Building Market Size is projected to reach USD 328.62 billion in 2029, at CAGR of 22.2% during forecast period [2022-2029] Pune, India, Sept. 28, 2022 (GLOBE NEWSWIRE) — The global smart building market size is expected to gain momentum by reaching USD 328.62 billion by 2029 while exhibiting a CAGR of 22.2% between 2022 to 2029. In its report titled “Smart Building Market Trends, 2022-2029,” Fortune Business Insights mentions that the market stood at USD 67.60 billion in 2021. Smart buildings comprise building operations and control systems sensors, microchips, and other components. The building offers low operational costs, building performance, efficient security management, tenant management, and performance management. Smart city projects and the emergence of 5G technology...

Continue reading

With 13.9% CAGR, Touch Screen Display Market Size worth USD 166.12 Billion in 2029

As per the report by Fortune Business Insights, the global Touch Screen Display Market size is projected to reach USD 166.12 billion in 2029, at a CAGR of 13.9% during the forecast period, 2022-2029 Pune, India, Sept. 28, 2022 (GLOBE NEWSWIRE) — The global Touch Screen Display Market Size stood at USD 59.57 billion in 2021. The market is anticipated to surge from USD 66.91 billion in 2022 to USD 166.12 billion by 2029 at a 13.9% CAGR during the forecast period. Fortune Business Insights™ has deep-dived these inputs in its latest research report, titled, “Touch Screen Display Market, 2022-2029.” According to the analysis, predictive touch technologies have gained considerable traction to provide more design flexibility. Besides, gesture trackers, including vision-based and RF-based sensors, have become highly sought-after in consumer...

Continue reading

Teleflex Completes Acquisition of Standard Bariatrics

Differentiated Stapling Technology for Bariatric Surgery WAYNE, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of Standard Bariatrics, Inc., which has commercialized an innovative powered stapling technology for bariatric surgery. On August 22, Teleflex announced its entry into a definitive agreement to acquire Standard Bariatrics. Under the terms of the agreement, Teleflex acquired Standard Bariatrics for $170 million at closing, with additional consideration of up to $130 million payable upon the achievement of certain commercial milestones. For 2022, the transaction is not expected to contribute meaningfully to Teleflex revenue and is expected to be approximately $0.10 dilutive...

Continue reading

THOR Industries Delivers Record Fourth Quarter And Fiscal 2022 Results

FISCAL 2022 NET SALES TOP $16.3 BILLION WITH EARNINGS PER SHARE OF $20.59 Fiscal Fourth Quarter 2022 HighlightsNet sales for the fourth quarter were $3.82 billion, an increase of 6.4% as compared to the fourth quarter of fiscal 2021. Consolidated gross profit margin for the fourth quarter was 17.5%, a 90 basis point improvement over the comparable prior-year period. Earnings per share for the fourth quarter were $5.15 per diluted share, an increase of 25.0% as compared to $4.12 per diluted share in the same period of the prior fiscal year. During the fourth quarter, the Board of Directors approved an additional authorization for share repurchases of approximately $450 million, raising the total authorization granted by the Board during fiscal 2022 to approximately $700 million.Fiscal Year 2022 HighlightsNet sales for fiscal year...

Continue reading

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy Company to Hold Extraordinary General Meeting Week of December 12, 2022 BERKELEY, Calif. and MAINZ, Germany, Sept. 28, 2022 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that its Nominating Committee and Board of Directors nominated Dr. Heiner Dreismann as Chairman of the Board and Gregory Tibbitts to its Board of Directors. The Company’s Board of Directors intends to call an extraordinary general meeting the week of December 12, 2022, to vote on the nominations. “As we continue to build strength throughout...

Continue reading

The merger of Evli Plc and EAB Group Plc will be completed and Evli publishes an exemption document

EVLI PLC STOCK EXCHANGE RELEASE SEPTEMBER 28, 2022 AT 2.00 PM (EET/EEST) NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. Evli Plc (“Evli”) and EAB Group Plc (“EAB”) announced on May 31, 2022 that Evli and EAB had signed a combination agreement (the “Combination Agreement”) and a merger plan (the “Merger Plan”) on the combination of the companies through a merger (the “Combined Company”). The combination of Evli and EAB is executed through a statutory absorption merger in accordance with the Finnish Companies Act whereby all assets and liabilities of EAB are transferred without a liquidation procedure to Evli (the “Merger”). The conditions of the completion of the merger The conditions of the completion according to the Combination Agreement...

Continue reading

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

STAMFORD, Conn., Sept. 28, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug Application (NDA) in Japan for approval of difelikefalin for the treatment of pruritus in hemodialysis patients. “The NDA submission represents important progress toward bringing difelikefalin injection to hemodialysis patients suffering from pruritus in Japan,” said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. “In collaboration with our partners, we look forward to making difelikefalin injection available to healthcare providers and hemodialysis patients around the world who...

Continue reading

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Clinical program advancement represents key milestone for Cornerstone underscoring its commitment to the development of lead compound, devimistat, in pancreatic cancer Cranbury, Sept. 28, 2022 (GLOBE NEWSWIRE) — September 28, 2022 – Cornerstone Pharmaceuticals, Inc., a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced the initiation of a Phase 1 clinical trial evaluating CPI-613® (devimistat) in combination with chemoradiation for the treatment of advanced pancreatic cancer. Devimistat is the company’s first-in-class lead compound designed to target enzymes that are involved in cancer cell energy metabolism found within the mitochondria of cancer cells. “The initiation of this Phase 1 trial is an important milestone for Cornerstone and demonstrates our continued commitment...

Continue reading

Microbix Announces Initiation of Normal Course Issuer Bid

Microbix to Repurchase up to 5% of its outstanding shares over 12 months MISSISSAUGA, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the initiation of a Normal Course Issuer Bid (“NCIB”) program for the repurchase and cancellation of outstanding common shares. Specifically, the NCIB enables Microbix to repurchase up to 6,949,568 Common Shares (“Shares“), that being approximately five percent (5%) of the 138,991,374 Shares outstanding as at September 26, 2022, through the facilities of the Toronto Stock Exchange (“TSX”) over a 12 month period starting on October 3, 2022 and ending on October 2, 2023. The actual number of Shares repurchased pursuant to the NCIB will be determined by management. The...

Continue reading

Kvalitena AB (publ) sells shares in MAHA Energy AB (publ)

On September 28th, 2022, Kvalitena AB (publ), Reg. No. 556527-3314, a company incorporated and registered in Sweden (“Kvalitena”), entered into a Share Purchase Agreement with vehicles managed by the Starboard group (“Starboard”) in which Kvalitena sold approximately 10% (ten percent) of the shares issued by Maha Energy AB (publ), Reg. No. 559018-9543, a public limited liability company incorporated under the laws of Sweden (“Company”), to Starboard.  Starboard is a Brazilian investment management firm with offices in São Paulo, Rio de Janeiro, and Madrid. Its extensive experience and credibility with market participants in the Brazilian space allow Starboard to find unique investment opportunities and provide solutions to highly complex situations. Starboard’s expertise has enabled the development...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.